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564 R. Gramignoli et al.that disease. Other biochemical functions normally performed by the liver are present and presumably “normal” in these
hepatocytes. Hepatocytes were isolated from the liver of 35 organ donors and 35 liver tissues taken at OLT from patients with
liver disease were analyzed for 9 different measures of viability and function. The data indicate that cells isolated from some
diseased livers performed as well or better than those isolated from organ donors with respect to viability, cell yield, plating
efficiency and in assays of liver function, including drug metabolism, conjugation reactions and ammonia metabolism. Cells
from metabolic diseased livers rapidly and efficiently repopulated a mouse liver upon transplantation. Conclusions: As with
domino liver transplantation, domino cell transplantation deserves consideration as method to extend the pool of available
organs and cells for transplantation.
© 2013 Elsevier B.V. All rights reserved.Introduction
Transplantation of hepatocytes (HTx) has been shown to be
useful for patients with chronic or acute liver failure or
genetic defects in liver function (Strom et al., 1997; Fisher
et al., 2000; Fisher and Strom, 2006; Strom et al., 2006; Fox et
al., 1998; Horslen et al., 2003; Muraca et al., 2002; Dhawan et
al., 2006; Stephenne et al., 2006; Lee et al., 2007; Meyburg et
al., 2009a; Mitry et al., 2004). The most common indications
of HTx are liver-based inborn metabolic disorders. Because of
large redundancies of function, the entire hepatic capacity is
not normally required to maintain homeostasis. The main
source of cells for HTx is livers rejected for transplantation
(Strom et al., 2006; Meyburg et al., 2009b; Hughes et al.,
2006). Steatosis is the most common cause for rejection of a
tissue for transplantation. Low cell viability, yield and drug-
metabolizing enzyme activity has been reported in hepato-
cytes obtained from fatty livers (Donato et al., 2006).
Domino liver transplantation (DLT) of organs from patients
with metabolic diseases has been used to increase the number
of organs available for transplant (Ericzon et al., 2008;
Mazariegos et al., 2012; Popescu and Dima, 2012). The world
registry lists 790 such transplants through 2009 (Roels and
Rahmel, 2011). Themetabolic disease in the donor liver either
should not induce the disease in the recipient, or would be
expected to produce symptoms of the disease only after many
years. Unlike DLT, where the entirety of the liver is rapidly
replaced with one with a metabolic disease, HTx generally
results in replacement of b10% of the recipient liver with
donor cells. Since most metabolic disease hepatocytes would
not induce the symptoms of the disease in the recipient,
hepatocytes from donors with metabolic diseases might be
useful for transplantation if they could be isolated in useful
numbers and retained sufficient viability and function. Here
we examined the viability, cell yield and metabolic activity of
hepatocytes isolated from organ donors and tissues obtained
from patients receiving OLT for metabolic and other types of
liver diseases. The results indicate that hepatocytes with high
viability and function can be isolated from organs removed at
the time of OLT from patients with diseased livers. If the
diseases of the donor and recipient are carefully considered,
these organs could provide a useful source of cells for clinical
transplantation.
Materials and methods
Human liver tissues were collected under IRB protocol 0411142
and hepatocytes were isolated from 35 organ donors (OD) andfrom 35 liver tissues obtained from patients receiving OLT for
metabolic and other liver diseases (MD). Liver tissue from organ
donors was flushed with either Belzer's UW solution or HTK
depending on the solution preferred by the procurement
agency. Metabolic disease cases were recovered in the OR
and flushed with either Belzer's UW solution if stored for
more than 90 min or ice-cold Eagle's MEM if the tissues were
taken to the lab immediately for isolation. Hepatocyte
isolation and culture were performed as previously de-
scribed (Gramignoli et al., 2012; Kostrubsky et al., 1999).
Methods to assess cell viability, plating efficiency, or ammonia,
testosterone and 7-ethoxyresorufin metabolism, resorufin
conjugation, media and culture conditions were as previously
described (Gramignoli et al., 2012). Cell-based assays for
specific CYP (1A2; 2C9; 3A7; 3A4, Promega Corporation,
Madison, WI, U.S.A.) were used according to the manufac-
turer's instructions. Results were expressed as Luminescent
Counting Unit (LCU)/min and normalized to a million of viable
cells (suspension cultures) or to the double strand DNA content
(adherent cultures) measured, after the Glo™-assays are
complete, by Quant-iT™ PicoGreen® dsDNA kit according to
the manufacturer's instructions (Molecular Probes, Invitrogen,
Camarillo, CA).
Animal transplant
Animal studies were reviewed and approved by the Institu-
tional Animal Care and Use Committee. Human hepatocytes
(106/mL in Eagle's Minimal Essential Medium; Lonza) were
transplanted in FRG mice as previously described (Azuma et
al., 2007).
Statistical analysis
Statistical differences were determined by comparing means
using analysis of variance with repeated measurements and
Dunnett's post hoc test, p b 0.05 was chosen as the minimum
level of significance. Data were analyzed by GraphPad Prism
(version 5.03, GraphPad Software Inc.).
Results
Hepatocytes were successfully isolated from 70 hepatic
tissues; 35 were obtained from organ donors (OD) rejected
for OLT, and 35 were tissues were obtained from the
explanted liver of patients who received OLT for metabolic
and other types of liver disease (MD) including, biliary atresia,
565Domino hepatocyte transplantand PNALD as described in Table 1. The average age of the OD
group was 41 ± 4 (mean ± SEM) years (Fig. 1). Metabolic
and disease livers were obtained from younger individuals
(8 ± 2 years), with a gender distribution of 2:1 (M/F). The
cell yield, normalized to millions of viable cells per gram of
tissue, was nearly 1.5 times higher in the MD group as
compared to the OD group. Gender does not significantly
affect the isolation outcome, while younger donors are
normally providing more viable hepatocytes per gram of
processed tissue. Nevertheless, no significant differences
were observed between ODs and MDs in terms of cell recovery.
A viability of 60% would still be considered useful for a
clinical transplant. Only one sample from the OD group and 3
from the MD groups were below this level of viability (Fig. 1D).
As expected, theMD cases with low viability were from cirrhotic
livers, from an A1AT patient and two cases with biliary atresia.
Taken together, there were no significant differences in
viability between the OD and MD groups (79 ± 2% and 82 ± 3%,
respectively).
The level of apoptosis, as measured by caspase activity in
cells, was not different between the two groups: specimens
with the highest caspase activity were those obtained from
the liver failure (ALF and PNALD) and cirrhotic (biliary
atresia) cases (Fig. 1E).
Plating efficiency measures the ability of cells to attach
to culture dishes and remain attached for the first 24 h.
Since attachment requires continued energy expenditure by
the cells, it is a more robust test of viability than Trypan blue
exclusion. Plating efficiency was measured on 56 samples,
equally distributed between the OD and MD groups. There
was no significant difference in the plating efficiency between
MD and the OD groups (Fig. 1F). Only two of the MD cases and 4
of the OD cases displayed less than a 50% plating efficacy. In
both groups, cells showed typical hepatocyte morphology:
polygonal shape, granular cytoplasm with small vesicular
inclusions, one or more nuclei and sharp and bright cell
membranes with canalicular structures readily visible be-
tween adjacent hepatocytes (Fig. 2). Isolated cells from the
MD cases showed remarkably normal morphology, particularly
when the gross morphology of the native liver tissue wasTable 1 Characteristics of the liver tissues investigated. Livers from
prolonged cold ischemia time (up to 22 h), anoxia, drug abuse or steato
cases collected, the age and gender of the donor. A small portion of t
flushed and transported to the lab for cell isolation. Cold ischemic tim
Metabolic disease Abbreviatio
Methylmalonic acidemia MMA
Primary hyperoxaluria PHO
Maple Syrup Urine Disease MSUD
Crigler–Najjar syndrome CN
Ornithine transcarbamylase deficiency OTC
Carbamoyl-phosphate synthetase 1 deficiency CPS-1
Citrullinemia Cit
Congenital hepatic fibrosis CHF
Parenteral nutrition associated liver disease PNALD
Alpha-1-antitrypsin deficiency A1AT
Familial cholestasis FC
Biliary atresia BA
Acute liver failure ALFconsidered (Fig. 2F). Parenchymal hepatocytes made up N95%
of the attached cells by visual inspection.Metabolic activity of isolated cells
Isolated cells must display robust biotransformation activity
to support liver function. Hepatic cytochrome P450 enzymes
metabolize drugs and other xenobiotics as well as endoge-
nous substances such as hormones. Data in Figs. 3 and 4
summarize the activities measured in isolated cells with
substrates for CYP1A, CYP2C9, CYP3A4 and CYP3A7. For CYP1A
we employed two differentmeasures of activity, a luminescent
(Luciferin-ME) and a fluorescent assay (EROD). Testosterone is
metabolized in a regioselective manner by CYP3A4. Hydroxyl-
ation of testosterone on the 6β position is a common measure
of CYP3A4 activity. High-pressure liquid chromatography was
used to separate and quantify testosterone metabolism to
6-betahydroxytestosterone to assess CYP3A4 mediated activi-
ty. Cells obtained from the two different tissue sources, ODs
and MDs, were analyzed as a rapid readout protocol, within 2 h
of isolation for CYPs1A1, 1A2, 2C9, 3A7 and 3A4, n = 61 (Fig. 3)
and, when possible (n = 50), with cells maintained in culture
with and without exposure to prototypical inducing agents on
the final 3 days of a 5 day culture period, β-naphthoflavone
(BNF), rifampicin (Rif) or phenobarbital (PB) (Fig. 4).
The conversion of 7-ethoxyresorufin to resorufin (EROD) is a
measure of CYP1A activities. Similar EROD activities were
measured in both the OD and MD groups immediately after
isolation (1.0 ± 0.3 and 1.1 ± 0.3 pmol/min/million in the OD
and MD hepatocytes, respectively, Fig. 3A). The metabolism of
a luminescent probe (Luciferin-ME), reported to be specific for
CYP1A2 activity was also examined. In general, the results with
Luciferin-ME agree well with the EROD assay. Although specific
cases in each group showed low activity, taken together, no
significant differences were observed between the hepato-
cytes isolated from the OD and MD groups (Fig. 3B). Metabolism
dependent on CYP3A4 activity in hepatocytes was measured by
testosterone and with Luciferin-IPA metabolism. A 1.6 fold
higher capacity tometabolize testosterone was noted in MD, asorgan donors were those rejected for transplantation, mainly for
sis. Also listed are themetabolic and diseased livers, the number of
he right lobe was dissected in the OR immediately after explant,
es ranged from 1 to 12 h.
n n Gender Age
1 M 24 years
1 M 13 months
9 M (6)/F (3) 16 months–28 years
4 M (2)/F (2) 13 months–23 years
2 M (1)/F (1) 2–25 years
2 F 6–15 months
1 F 2 years
1 F 14 years
2 M (1)/F (1) 18 months
1 M 10 years
1 M 14 months
7 M (4)/F (3) 6–12 months
3 M (2)/F (1) 18 months–12 years
Figure 1 Age, tissue weight, viable cell yield, viability, apoptosis and plating efficiency of hepatocytes. (A) Box-and-whisker plot
showing median, 25- and 75-percentiles and min and max values of OD and MD tissue samples (n = 70); (B) scatter plots of wet tissue
weights of tissues used for cell isolation (n = 70). Bar graphs representing (C) viable cell recovery (n = 70); (D) percentage of viable
hepatocytes (n = 70); (E) caspase 3/7 activity measured immediately after isolation (n = 34); (F) percent of cells attached to a collagen
substrate after 24 h in culture (n = 56). Bars show mean and standard error in groups with more than one sample; nd = evaluations not
done.
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(Fig. 3C). Using the luminescent CYP3A4 assay, Luciferin-IPA
showed a 2-fold increase in metabolism. Both CYP3A4 assays
showed a similar profile of activity with specific samples
(Fig. 3D). Another CYP3A family member, CYP3A7, is expressed
at highest levels in fetal liver and its expression gradually
declines over the late fetal, neonatal and pediatric life (Hines
and McCarver, 2002). Since one OD sample and 50% of the MD
samples were obtained from patients under 3-years of age, a
timewhen significant levels of CYP3A7 could still be expressed,
we examined CYP3A7 activity with Luciferin-PFBE as thesubstrate. The OD group contained older donors and, as
expected, showed significantly lower CYP3A7 activity compared
to the younger MD group (p = 0.0125) (Fig. 3E). Measurements
of CYP2C9 activity showed a similar profile as that observed
with CYP3A4 and 7 (Fig. 3F).
Cytochromes in the 1A, 2C and 3A families have a
characteristic that prior exposure to specific compounds will
result in the induction of the expression and activity of these
enzymes in hepatocytes. Thus, the ability to induce the
expression of these CYPs with prototypical inducers is a robust
test of the capacity of the cells to survive in culture for 5 days,
Figure 2 Phase-contrast photographs of human hepatocytes
isolated from OD and MD cases. Representative photographs taken
on day 5 of culture, bar = 40 μm. (A) OD, (B) primary hyperoxaluria;
(C) Maple Syrup Urine Disease; (D) Crigler–Najjar syndrome;
(E) biliary atresia; (F) explant liver from a biliary atresia patient
prior to cell isolation.
567Domino hepatocyte transplantand respond as they would, in vivo, with regulated RNA
expression, increased de novo synthesis of proteins that are
fully functional and can be quantified as increasedmetabolism
of specific CYP substrates.
Data presented in Fig. 4 show the response of hepato-
cytes from the OD and MD groups to specific CYP induction
protocols. As shown in panel (A), prior exposure to BNF
induced CYP1A activity in both OD and MD cases. Even cases
with low basal activity such as PHO and BA could be induced
more than 2-fold by BA exposure. Cells from the MMA patient
showed the highest basal levels of activity, more than 3-fold
higher than the OD controls. Metabolism mediated by
CYP3A4 measured as testosterone metabolism (B) or the
luminescent IPA assay (C) was measured in the OD and MD
groups. While MD donors tended towards higher basal activities
than the OD, the results were not significantly different. Both
groups were readily induced by prior exposure to PB or Rif with
induction greater than 7-fold over basal levels. The lowest
CYP3A4 levels were measured in the cirrhotic cases, A1AT and
BA.
As described earlier, CYP3A7 is the CYP3A family member
expressed at highest levels in fetal and early postnatal life.
As shown in Fig. 4D, CYP3A7 is expressed at low levels in the
OD group and was not significantly induced by prior exposure
to PB or Rif. However, the MD group contains many pediatric
patients, and CYP3A7 activity was readily measured and was
induced by Rif or PB in most of the MD cases. On average, the
basal CYP3A7 activity is 10-fold higher in the MD than in the
OD group. There were noticeable differences among theinborn errors in the MD groups: the urea cycle defects (OTC
and CPS-1) showed robust induction, both in terms of 3A7
(5–12 fold increase) and 3A4 isoforms (10–27 fold). CHF
showed a modest induction of CYP3A4, but the greatest
induction in terms of CYP3A7 activity, 35–54-fold, but this
high ratio is due in part, to an extremely low basal level.
Conjugation
Phase II activities, such as conjugation reactions with sulfate,
glucuronide or glutathione, are generally considered to be
detoxification processes that aid in the elimination of endoge-
nous or xenobiotics from the body. In freshly isolated cells
conjugation of resorufin was comparable in OD and MD-derived
hepatocytes (Fig. 5A) and was well maintained in cells in
longer-term cultures (5B). Interestingly, cells from the Crigler–
Najjar cases, showed no capacity to conjugate resorufin
immediately upon isolation (p = 0.0004), but normal metabolic
activity was restored to normal levels by day 5 when cells were
maintained in culture.
Ammonia metabolism
Ammonia metabolism was measurable in 8 of 11 MD cases
examined and the range of activities was similar to that
observed in the OD group. Ammonia metabolic capacity was
completely absent in PHO and CHF cells immediately after
isolation (Fig. 5C) but was restored to normal levels (or
above) when the cells were cultured for 5 days (Fig. 5D). As
expected, cells from patients with urea cycle defects
displayed no capacity to metabolize ammonia at any time
point. If urea cycle defect cases are removed from the
analysis, the MD group displayed a greater ability to
metabolize ammonia, compared to OD cases (147 ± 18 vs
95 ± 13 nmol/min/mg, respectively).
Cell transplantation
Hepatocytes isolated from the metabolic disease cases showed
excellent viability and function so their transplant potential
was examined as the ability to repopulate the liver of an
immunodeficient host. Hepatocytes from 5 different MDs were
transplanted into Fah−/−/Rag2−/−/Il2rg−/− (FRG) mice as
described by Azuma et al. (2007), and human albumin levels
were recorded (Fig. 6A). Robust growth of donor hepato-
cytes was evident from elevations in circulating albumin, to
values that correspond to 50–99% repopulation with human
cells.
Staining by FAH antibody allowed identification of human
hepatocytes (positive cells) (Fig. 6B) distributed in the liver
lobules, around portal and central veins, and inside the
parenchyma, in a range between 40% and 80% of repopulation
(Figs. 6C, D).
Discussion
Experiments presented here examined the viability, cell
yield and metabolic activity of hepatocytes isolated from
liver tissue obtained from organ donors or explanted liver
tissue obtained at the time of OLT from patients with
Figure 3 Metabolic functions in freshly isolated hepatocytes from OD and MD cases. CYP1A1/2 activity measured as (A) EROD
activity or (B) Luciferin-ME; CYP3A4 measured as (C) 6-betahydroxytestosterone formation or (D) Luciferin-IPA; (E) CYP3A7 activity
measured with Luciferin-PFBE; (F) CYP2C9 activity quantified with Luciferin-H; (n = 61); nd = evaluation not done.
568 R. Gramignoli et al.metabolic and other types of liver disease including biliary
atresia, acute liver failure and parenteral nutrition associated
liver disease. To simplify the discussion of a wide range of liver
diseases, we refer to all tissues derived from explanted livers
obtained at the time of OLT as MD.
Domino liver transplantation is used to increase the
number of liver grafts available for OLT (Ericzon et al., 2008;
Wilczek et al., 2008). In a recent review Popescue and Dima
stress that livers from patients with metabolic liver disease can
be safely transplanted if the donor's defect and the recipient's
metabolic needs are carefully considered (Popescu and Dima,
2012). Liver from patients with many metabolic diseases is
morphologically and biochemically normal, except for themutation that characterizes that disease. Other biochemical
functions performed by the liver are “normal” in these
hepatocytes. Data presented here supports this hypothesis,
as cells from most MD cases performed as well or better
than OD cases in assays of liver function, including drug and
ammonia metabolism and conjugation. Thus, hepatocytes
from a Crigler–Najjar explant, could be expected to metab-
olize ammonia normally if transplanted into an OTC patient
(Fig. 6).
The aim of DLT is to correct the immediate liver problem
and not to produce symptoms of the donor's disease in the
recipient for many years, if at all. With whole organ DLT, the
entirety of the metabolic defect in the liver is immediately
Figure 4 Long-term metabolic activity and CYP450 inductions. Metabolic activities measured in hepatocytes isolated from OD or
MD. Cells were cultured for 2 days in regular maintenance media. In the indicated cultures, the inducing agents were added to culture
media for 3 additional days. Control cultures were replenished daily with fresh media without inducers but with the vehicle (0.1%
DMSO). All activities were measured on day 5 of culture (n = 50). The small black area at the base of each bar represents the activity
measured in control cultures treated with vehicle (DMSO) and the open or shaded area above, represents the activity measured following
a 3-day exposure to the indicated compound. (A) CYP1A1/2 activity, white bars are data from cells induced with BNF; (B, C) CYP3A4
activity, shaded bars represent cells pretreated with PB or Rif, respectively; (D) CYP3A7 activity in control (black) vs PB or Rif-treated
hepatocytes (shaded bars); nd = evaluation not done.
569Domino hepatocyte transplanttransferred to the recipient. Since hepatocyte transplantation
only replaces a small portion of the liver, domino hepatocyte
transplantationmay have greater appeal than DLT. Because of
the redundancy in function for most biochemical pathways in
the liver, as little as 5–20% normal function of specific
pathways may be sufficient to keep the individual symptom
free. Hepatocyte transplants aim to provide the 5–20% of
missing enzyme activity. Far less than 20% repopulation has
been accomplished in clinical HTx. Transplant procedures and
techniques are currently being revised to include pretreat-
ments such as portal embolization or low dose radiation to
a defined portion of the liver to improve engraftment and
repopulation of recipient liver with donor cells, however,
there are no reports of clinical experience with these
techniques. With current techniques, if OTC-deficient cellswere transplanted into Crigler–Najjar recipients, there would
be no risk of transferring OTC deficiency to the recipient. The
80–95% of native hepatocytes easily performs the ammonia
metabolism required, while the 5–20% OTC-deficient donor
cells could conjugate bilirubin to correct the defect in the CN
recipient.
Hepatocyte isolation from organs removed from meta-
bolic disease patients has some advantages for HTx pro-
cedures. These organs are readily available from OLT cases
at the major transplant centers; the same places where HTx
would be conducted. TheMD organs are immediately available
for cell isolation with little to no cold ischemic time. Another
important advantage is that these donors are living donors and
they would not have the negative effects typical of a
brain-dead donor. A major advantage of MD donors is their
Figure 5 Conjugation and ammonia metabolism. Bars represent conjugation or ammonia metabolism from OD and MD hepatocytes
(A, C) immediately after isolation (n = 54) and (B, D) in cells cultured in maintenance media for an additional 5 days. (n = 50). No CN
cases (n = 3) displayed any conjugation capacity towards resorufin, **p = 0.0004. As expected, cells from urea cycle defect patients
(OTC, CPS-1 and Cit) showed no capacity to metabolize ammonia, nd = evaluation not done.
570 R. Gramignoli et al.age. In our study the average age of the MD donors was
approximately 8 years, and 22 of the cases procured for this
study were from donors 5 years or younger. Hepatocytes from
younger donors would be expected to have higher prolifera-
tive capacity than cells from aged donors. As reported here,
viability and cell yields are generally excellent (Fig. 1). Since
these organs can be brought to the GMP facility for cell
isolation, no additional facilities would be needed. Like all
organ donors, these donors would require regular serological
screening prior to their use for transplantation. Although all
tissues received from MD donors over a 30-month period were
analyzed and reported here, one would not expect that every
MD organ could be used for hepatocyte transplant procedures.
Cells from patients with metabolic diseases such as MSUD,
where extrahepatic organs and tissues can contribute to the
overall function of that pathway, would be consideredextremely useful for HTx. Domino transplants of livers from
MSUD patients have clearly shown that recipients have
normal branched chain amino acid levels even while on a
normal protein diet (Mazariegos et al., 2012). One would
expect virtually no risk of imparting MSUD to any HTx
recipient. Organs that show minimal histopathological abnor-
malities are the most useful, while those from cirrhotic livers
the least useful. Organs from patients with urea cycle defects,
Crigler–Najjar and MSUD display normal to near normal gross
morphology, histology and vascularity. Cell isolation from
these tissues is efficient and billions of viable hepatocytes
could be isolated from these organs.
Careful matching of themetabolic capabilities of the donor
and need of the recipient is critical. If the donor defect would
not be expected to have an immediate adverse effect on the
recipient, their use could be considered. While cells from an
Figure 6 Human hepatocyte transplantation in Fah−/−/Rag−/−/Il-2rg−/− mice. (A) Repopulation of the liver of FRG mice with human
hepatocytes isolated from organ donors (n = 3) or 5 different metabolic disease patients including MSUD, CN-1, FC, BA or OTC-deficiency.
EachMD case repopulated the liver as quickly and effectively as cells fromnormal organ donors. (B) Human hepatocytes in themouse liver
from an OTC deficient patient identified by reactivity with antibodies to FAH (brown color). Animals were maintained for approximately
3 months prior to sacrifice, scale bar: 25 μm. (C) Serial sections of transplanted human hepatocyte stained with anti-FAH antibodies,
scale bar = 50 μm and (D) H&E, showing the histology of the liver tissue repopulated with human hepatocytes; scale bar: 50 μm.
571Domino hepatocyte transplantMSUD or a Crigler–Najjar donor might be useful for an acute
liver failure patient, cells from donors with urea cycle defects
would not likely be useful because of the immediate need for
ammonia metabolism in the ALF recipient.
We do not advocate the use of cells from every diseased
liver. Although we performed isolation on biliary atresia and
acute liver failure cases, these cells would not be recommended
for clinical transplants because of concerns for cell yield,
viability and function.
There is evidence from our study, of extreme resilience in
hepatocytes isolated from patients with metabolic liver disease
and for recovery of hepatic function when the hepatocytes are
removed from the donor. For example, ammonia metabolism
improved in the PHO, CN, and CHF cases in cells cultured for
5 days as compared to measurements made immediately after
isolation. Conjugation of resorufin was completely absent in the
cells from the CN cases, however, after 5 days in culture the
cells showed normal activity. Resorufin conjugation could be
expected to recover, even in CN cases, because resorufin is
conjugated by up to 9 different UGT enzymes, with UGT1A6 and
1A9 the most active (Tolando et al., 2012). While UGT1A1 (the
formmutated in CN cases) remains inactive in the CN cells, data
presented here indicate that the remaining UGTs recover
activity in hepatocytes removed from the CN environment.
The observations made from hepatocytes explanted from
metabolic disease cases have provided clinical guidance forhepatocyte transplants. High CYP3A4 activities were noted in
the OTC patients. When HTx was performed on these patients,
because of the high CYP3A4 levels, normal doses of Tacrolimus
were rapidly cleared resulting in insufficient immunosuppres-
sion until dosage could be adjusted. Significantly higher doses
of Tacrolimus were required to maintain therapeutic levels.
Two recent CN patients received HTx and whose immunosup-
pression post hepatocyte transplantation included Tacroli-
mus, prednisolone and mycophenolate mofetil (MMF). As we
predicted from CN hepatocytes, conjugation was impaired,
and a complete absence of mycophenolate glucuronide was
noted in blood samples taken during the first post-transplant
week. The patient registered extremely high mycophenolic
acid levels when a normal dose of MMF was administered
(533 mg*h/L; therapeutic range 30–60 mg*h/L). Their
inability to metabolize the drug necessitated that MMF be
discontinued. A subsequent patient was treated with a reduced
dose of MMF. Samples taken during the first two post-transplant
weeks showed a small, but gradually growing peak in the
chromatograms at a retention time similar to mycophenolate
glucuronide, suggesting that conjugation of mycophenolic acid
is returning to normal over time, again, as predicted from
experiments with the cultured cells. We are currently
investigating drugs, diet and other factors that might
influence these metabolic activities in such a disease-
specific manner.
572 R. Gramignoli et al.Bhogal et al. recently reported the isolation of hepatocytes
from diseased livers (Bhogal et al., 2011). Their disease
selections were quite different from those in the current
study, in that they focused on cirrhotic and fibrotic tissues from
patients with alcoholic liver disease, primary biliary cirrhosis
and primary sclerosing cholangitis. They reported an experi-
ence similar to ours in that the viability, total cell yield and the
success rate with cirrhotic tissues were low. Like theirs, our
experience suggests that cirrhotic tissues would not provide
enough cells from a single donor for clinical transplantation.
For the studies reported here with tissue from metabolic
disease patients, we generally procured less than 1/10 of the
total liver weight for isolation. Given the viability and cell yield
reported here, even one lobe from many metabolic disease
organs could provide billions of cells, enough for one or more
clinical transplants. Transplants of MD cells to FRG immunode-
ficient mice support the hypothesis that these cells would
perform well post transplantation as was evident from the
robust growth and albumin secretion from cells from 5
metabolic donors in parallel with 3 “normal” ODs (Fig. 6A).
Since each mg of human albumin correlates with 15–20%
repopulation, these animals show 50–99% repopulation with
human hepatocytes by 3 months post transplant. Analysis of
the liver of FRG mice transplanted with human hepatocytes
isolated from metabolic diseased patients resulted in a rapid
and efficient repopulation of the liver. There were no
differences in the levels of repopulation of the liver with
diseased cells or those isolated from normal organ donors
(Figs. 6B, C).
While it is clear that not all cases will be useful, as with
DLT, domino hepatocyte transplantation should be consid-
ered a transplant option. The use of cells from a different
metabolic disease would require careful consideration of
donor function and recipient's needs. However, in an age
where a number of options to extend the pool of available
organs and cells for transplantation are being considered,
including xenotransplantation of organs or cells from animals,
recycling human hepatocytes from patients with metabolic
liver disease for domino hepatocyte transplantation deserves
consideration. During the writing of this manuscript, a paper
from Stephenne et al. appeared reporting that a domino
hepatocyte transplant was conducted on a child with phenyl-
ketonuria from a donor liver with a glycogen storage disease,
affirming the hypothesis that these organs should be
investigated for safety, efficacy and possible transplanta-
tion (Stephenne et al., 2012).Acknowledgment
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